Evidence map›Paper›PMID 39910654›Full record

ArticleInternational journal of cancer2025

Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.

Huijun Xu, Xuebing Fu, Shuyun Wang, Yihui Ge, Lu Zhang, Juan Li, Fang Zhang, Yang Yang, Yifu He, Yuping Sun and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huijun XuJinan Central Hospital, Shandong University, Jinan, Shandong, China.
Xuebing FuDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Shuyun WangPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yihui GePhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Lu ZhangDepartment of Oncology, The Fourth People's Hospital of Zibo, Zibo, Shandong, China.
Juan LiPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Fang ZhangDepartment of Oncology, Central Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
Yang YangDepartment of Ultrasound, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Yifu HeDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0003-1990-0298
Yuping SunPhase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID 0000-0002-0804-6850
Aiqin GaoDepartment of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID 0009-0009-3596-6669

Funding

Beijing Science and Technology Innovation Medical Development Foun-dation KC2023-JX-0288-PQ88Chinese Society of Clinical Oncology-Gilead Cancer Research Foundation Y-Gilead2024-PT-0148Health Commission of Anhui Province Scientific Research Project AHWJ2023A30183Health Commission of Anhui Province Scientific Research Project AHWJ2023BAc10031Key R&D Program of Shandong Province 2022CXGC010510National Natural Science Foundation of China 82103340National Natural Science Foundation of China 82103466Shandong Provincial Natural Science Foundation ZR2021MH268the Jinan Science and Technology Innovation Program of Clinical Medicine 202134041the Jinan Science and Technology Innovation Program of Clinical Medicine 202225015Wu Jieping Medical Foundation 320.6750.2023-05-51
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have shifted the treatment paradigm of non-small cell lung cancer (NSCLC) over the last decade. Despite notable therapeutic advancements in responders, the response rate remains limited owing to the immunosuppressive tumor microenvironment (TME). Therefore, to improve the efficacy of ICIs, it is essential to explore alternative targets or signals that mediate immunosuppression. Immunoglobulin-like transcript (ILT) 5 is a negative regulator of immune activation in myeloid cells. However, the expression and function of ILT5 in NSCLC remain unknown. Here, we found that ILT5 was highly expressed in tumor-associated macrophages (TAMs) of NSCLC tissues and predicted poor patient survival. Functionally, ILT5 induces the M2-like polarization of TAMs, which subsequently decreases the density of T cells, and increases FOXP3

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMembrane GlycoproteinsReceptors, ImmunologicTumor-Associated MacrophagesAnimalsCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsImmune ToleranceMaleMicePrognosisTumor MicroenvironmentImmune Checkpoint InhibitorsLILRB4 protein, humanMembrane GlycoproteinsReceptors, Immunologicimmunoglobulin‐like transcript 5M2‐like polarizationnon‐small cell lung cancerT cell immunitytumor‐associated macrophages

Identifiers

PMID39910654
PMCPMC11970544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.